Inflammatory diseases leading to deterioration of the small blood vessels. Anti-neutrophil cytoplasmic antibodies (ANCA) are a group of antibodies directed at cytoplasmic components of neutrophilic granulocytes. They are classified into cytoplasmic (cANCA) and perinuclear (pANCA) according to their immunofluorescence pattern on ethanol fixed human neutrophils. The two target autoantigens are Proteinase 3 (PR3) and Myeloperoxidase (MPO) respectively. PR3 has a high specificity for Wegener’s Granulomatosis and MPO is reported in a variety of vasculitides.
The recommendation of the ANCA standardisation committee is that the initial screening for ANCA should be performed by immunofluorescence as 5-10% ANCA positive samples in patients with vasculitis are only positive by immunofluorescence and negative on the antigen specific immunoassays. The types of immunofluorescence reactions that may be visualised on human polymorphonuclear neutrophils (hPMN) cells include cytoplasmic (cANCA), perinuclear (pANCA), atypical pANCA, ANA, and negative reactions. Immco ANCA IFA slides are available through CLS.
Anti-MPO and anti-PR3 antibodies can be characterised by BlueDiver Dot, ANCAGDIV-24 or individual ELISA assays available through CLS.
Antibodies are targeted to a component of the glomerular basement membrane (GBM). Anti-GBM are the primary pathogenic autoantibodies inducing glomerulonephritis in all patients with Goodpasture Syndrome.
Circulating ant-GBM antibodies can be detected with immunofluorescence on kidney tissue or ELISA or BlueDiver Dot.
|Code||Description||MSDS||Instructions for use|
|1140||ANCA (ethanol fixed substrate) IFA|
|2Z9671G||MPO Test System|
|2Z9691G||PR-3 Test System|
|ANCAGDIV-24||BlueDiver ANCA + GBM 3 Parameters|
|5154||ImmuLisa™ Anti-Glomerular Basement Membrane (GBM) Antibody ELISA|
|1124||ImmuGlo™ Glomerular Basement Membrane|